Press Release

– Financing co-led by Juvia Group and Lightspeed Venture Partners, with participation from an expanded syndicate of leading healthcare investors – – Dibotatug is an investigational, first-in-class, pathogenic cell-depleting antibody in late-stage development for the treatment of rare blood cancers and other hematologic and autoimmune diseases – SAN CARLOS, Calif. Oct 29, 2026 (BUSINESS WIRE)

A local presence can help international life science investors connect with emerging companies, research environments and potential investment partners. For US venture capital firm Mission BioCapital, Copenhagen provides a base for developing these relationships across Denmark and Europe. In 2025, the firm opened its first European office at BioInnovation Institute (BII), with Partner Robert Blazej

Japan’s Astellas Pharma has tapped Boston computational discovery company AI Proteins in a drug discovery deal potentially worth $400 million. AI Proteins crafts miniproteins with the aid of its computational design platform that the company said have demonstrated binding activity “beyond what’s possible with traditional nature-derived biologics,” according to an Oct. 21 release. The concept

Pfizer has followed Eli Lilly into the Sec61 space, inking a $500 million deal with Enodia Therapeutics a week after its Big Pharma peer formed an $870 million pact with Gate Bioscience. Like Gate, Enodia is targeting the Sec61 channel to stop disease-driving proteins from reaching the cell surface, leading to their degradation. By selectively blocking

LANTERN Phase 1b/2a trial will evaluate Zag Bio’s lead program in people with Type 1 diabetes Study will assess safety and pharmacology, with C-peptide measured for early signs of efficacy CAMBRIDGE, Mass., October 5, 2026 — Zag Bio™, Inc., a biotechnology company working to set a new standard for treating autoimmune disease, today announced it

Co-led by new investor Mission BioCapital and existing investor Novo Holdings, with additional investment from existing syndicate member Sound Bioventures, and new investors the Ljungström family office, Innovestor Life Science, EIFO, Catalyze Capital, Modi Ventures, and Pappas Capital Company will now advance danegaptide, a pioneering, first-in-class oral treatment for Non-Proliferative Diabetic Retinopathy (NPDR), into a

Cloverleaf Bio Raises $33 Million Seed Financing to Advance Novel RNA-Based Cancer Therapeutics Oversubscribed round led by 4BIO Capital includes strategic investment from AbbVie Ventures, Lilly, and Boehringer Ingelheim Venture Fund, reflecting depth of industry interest in this novel RNA therapeutics platform Financing will support proof of concept in hepatocellular carcinoma and advancement of follow-on

— Up to eight winners to receive up to $500,000 each in pre-seed funding, incubator space, equity for discovery services, and expert mentorship— — New sponsors AbbVie, TIAP, Connecticut Innovations, CCRM, and Norton Rose Fulbright join existing partners Mission BioCapital, Ono Venture Investment, Alloy Therapeutics, HitGen, Goodwin, and van den Boom & Associates to support

INDIANAPOLIS, May 27, 2025 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) and SiteOne Therapeutics, Inc. (“SiteOne”), a private biotechnology company developing small molecule inhibitors of sodium channels to treat pain and other neuronal hyperexcitability disorders, today announced a definitive agreement for Lilly to acquire SiteOne. The transaction includes STC-004, a Phase 2 ready Nav1.8 inhibitor

CAMBRIDGE, Mass., April 30, 2025— Mission BioCapital (MBC) announced today that it has expanded the reach of its Platinum Program in Europe in a collaboration with BioInnovation Institute (BII), a Denmark-based nonprofit institute focused on accelerating life sciences innovation to benefit human and planetary health. Winners of this year’s Platinum Program are eligible for lab